AnaptysBio (ANAB) said Wednesday that it would discontinue further investment in experimental therapy ANB032 after a phase 2b trial in moderate-to-severe atopic dermatitis or eczema did not meet the primary and secondary endpoints.
The company said it would focus its resources and capital on its other investigational autoimmune drugs.
AnaptysBio said it expects to report top-line phase 2b data for rosnilimab in rheumatoid arthritis in February and top-line phase 2 data in ulcerative colitis in Q1 of 2026.
Shares of the company were up more than 2% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.